Announcements
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Addex to Present at the Swiss Equities Baader Conference
- Addex to Present at Biotech Showcase™ 2024
- Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
- Addex Creates Treasury Shares
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (ADXN:NAQ) closed at 16.10, 222.00% above the 52 week low of 5.00 set on Dec 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.99 |
---|---|
High | 17.05 |
Low | 13.99 |
Bid | 12.22 |
Offer | 17.00 |
Previous close | 15.41 |
Average volume | 15.12k |
---|---|
Shares outstanding | 1.54m |
Free float | 992.84k |
P/E (TTM) | -- |
Market cap | 23.17m USD |
EPS (TTM) | -209.76 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼